Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography

Daniela E. Oprea-Lager1,2*, Matthijs C.F. Cysouw2, Ronald Boellaard2, Christophe M. Deroose1,3,4, Lioe-Fee de Geus-Oei5,6, Egesta Lopci7, Luc Bidaut1,8, Ken Herrmann9, Laure S. Fournier1,10,11, Tobias Bäuerle12, Nandita M. deSouza1,11,13 and Frederic E. Lecouvet1,14

1 Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium, 2 Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, 3 Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium, 4 Nuclear Medicine & Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium, 5 Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 6 Biomedical Photonic Imaging Group, University of Twente, Enschede, Netherlands, 7 Nuclear Medicine Unit, IRCCS – Humanitas Research Hospital, Milan, Italy, 8 College of Science, University of Lincoln, Lincoln, United Kingdom, 9 Department of Nuclear Medicine, University of Düsseldorf-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany, 10 Paris Cardiovascular Research Center (PARCC), Institut National de la Santé et de la Recherche Médicale (INSERM), Radiology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hopital européen Georges Pompidou, Université de Paris, Paris, France, 11 European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria, 12 Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, 13 Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom, 14 Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium

Metastatic tumor deposits in bone marrow elicit differential bone responses that vary with the type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can change in morphology due to treatment effects and/or secondary bone remodeling. Hence, morphological imaging is regarded unsuitable for response assessment of bone metastases and in the current Response Evaluation Criteria In Solid Tumors 1.1 (RECIST1.1) guideline bone metastases are deemed unmeasurable. Nevertheless, the advent of functional and molecular imaging modalities such as whole-body magnetic resonance imaging (WB-MRI) and positron emission tomography (PET) has improved the ability for follow-up of bone metastases, regardless of their morphology. Both these modalities not only have improved sensitivity for visual detection of bone lesions, but also allow for objective measurements of bone lesion characteristics. WB-MRI provides a global assessment of skeletal metastases and for a one-step “all-organ” approach of metastatic disease. Novel MRI techniques include diffusion-weighted imaging (DWI) targeting highly cellular lesions, dynamic contrast-enhanced MRI (DCE-MRI) for quantitative assessment of bone lesion vascularization, and multiparametric MRI (mpMRI) combining anatomical and functional sequences. Recommendations for a homogenization of MRI image acquisitions and generalizable response criteria have been developed. For PET, many metabolic and molecular radiotracers are available, some targeting tumor characteristics not confined to cancer type (e.g. 18F-FDG) while
INTRODUCTION

Bone is a common site of secondary tumor deposits because, in addition to its rigid, calcified, outer cortex, it has a richly vascular inner marrow of bony trabeculae, stroma, haematopoietic tissue and fat (1). Within bone, it is the crucial balance between osteoblastic and osteoclastic elements that maintains its functional strength and rigidity. Metastatic deposits elicit differential responses from the osteoblastic and osteoclastic components, which vary with the type of malignancy and result in strikingly different appearances on imaging (2). In some cases, the tumor incites a predominantly osteoblastic response with a resulting increase in calcified sclerotic matrix, as in prostate and breast cancer (3). In other tumor types, the metastasis causes bony destruction (osteoclastic response) without exciting an osteoblastic response, so that metastases (e.g. kidneys, thyroid, lungs) appear lytic and expansile (3). Finally, the tumor cells can simply invade the marrow without influence on the mineral content of the bone (i.e. radio-occult metastases). In many instances there is a mixture of sclerotic, lytic and radio-occult types. As treatment response is often accompanied by an increase in bony sclerosis (“flare response”), it can be difficult to differentiate it from an osteoblastic response to the tumor itself (4). Moreover, once deformed by the presence of metastases, the rigid form of the bony skeleton does not usually remodel sufficiently after treatment to distinguish untreated from treated tumor. Therefore, on morphological imaging, especially X-ray based, evaluation of response to treatment of bone metastases remains difficult.

RECIST were presented more than 2 decades ago and rely principally on unidimensional size measurements (5). Nowadays, RECIST forms the mainstay of response evaluation of solid tumors to treatment and is universally used in clinical trials of solid tumors. Index lesions with well-defined margins, discernable from adjacent parenchyma are required for reproducible measurements, and specific modifications are set out for some tissues (short-axis measurements for lymph nodes, bi-dimensional measurements for brain lesions). However, because of the blastic response of bone to tumor or to treatment, and of the rigid nature of calcified bone where deformity of the cortex persists after treatment, bone lesions were considered unmeasurable by RECIST. Modifications to RECIST (i.e., RECIST 1.1) stated that bone metastases with soft tissue masses > 10 mm could be considered measurable index lesions (6). Nevertheless, as reduction of the soft tissue component renders the lesions unmeasurable by these criteria again, there remains a critical unmet need for a means of quantifying bone lesions and their response to treatment.

The advent of imaging modalities providing information about tissue microstructure or its metabolism has accelerated the identification of skeletal metastases. 18F-fluorodeoxyglucose (18F-FDG) PET/CT identifies secondary deposits within bone because of their increased glucose turnover. Its whole-body coverage and increasingly widespread availability has made it of primary importance in cancer staging, particularly in patients where the tumor pathology or molecular profile indicates a high metastatic risk (7, 8). Additionally, techniques such as WB-MRI with DWI have a high sensitivity for identifying highly cellular lesions such as tumors and have been incorporated routinely into the staging of some tumor types such as myeloma (9–11). Dynamic contrast-enhanced MRI (DCE-MRI) for quantitatively assessing vascularization within bone marrow in patients with multiple myeloma was found to be of prognostic significance for these patients (12, 13). While these techniques have their own limitations, they are not hampered by what makes bone lesions unmeasurable by RECIST 1.1 (i.e. radio-occult appearance, sclerotic response and persistent bone deformity on healing). The purpose of this manuscript is to review the MRI and PET techniques available for measuring bone metastases, their opportunities and challenges, and their applicability in various tumor types.

DIFFERENT CANCERS – DIFFERENT TYPES OF BONE METASTASES

At present, the incidence of bone metastases is 65-75% in advanced metastatic breast cancer, 65-75% in prostate cancer, 60% in thyroid cancer, 30-40% in lung cancer, 40% in bladder cancer, and 50-60% in pancreatic cancer. The incidence for other targeted radionuclides target specific molecular characteristics, such as prostate specific membrane antigen (PSMA) ligands for prostate cancer. Supporting data on quantitative PET analysis regarding repeatability, reproducibility, and harmonization of PET/CT system performance is available. Bone metastases detected on PET and MRI can be quantitatively assessed using validated methodologies, both on a whole-body and individual lesion basis. Both have the advantage of covering not only bone lesions but visceral and nodal lesions as well. Hybrid imaging, combining PET with MRI, may provide complementary parameters on the morphologic, functional, metabolic and molecular level of bone metastases in one examination. For clinical implementation of measuring bone metastases in response assessment using WB-MRI and PET, current RECIST1.1 guidelines need to be adapted. This review summarizes available data and insights into imaging of bone metastases using MRI and PET.

Keywords: bone metastases, MRI, PET, measurable, response
Bone metastases can be classified as osteolytic, osteoblastic, radio-occult, or as a mixed type. Osteolytic metastases are characterized by destruction of normal bone and osteoblastic/sclerotic metastases are characterized by deposition of new bone. Radio-occult lesions have no impact on the mineral content of the bone. Osteolytic lesions are predominantly present in multiple myeloma, renal cell carcinoma, melanoma, non-small cell lung cancer (NSCLC), non-Hodgkin lymphoma (NHL), thyroid cancer, Langerhans-cell histiocytosis and breast cancer, and osteoblastic lesions are present in prostate cancer, neuroendocrine tumors, small-cell lung cancer (SCLC), Hodgkin lymphoma and medulloblastoma (14). Mixed lesions can be found in gastrointestinal cancers and squamous cancers, and 15-20% of bone metastases of breast cancer can be either osteoblastic or mixed (14). Radio-occult lesions can be present in virtually all tumor types. The mechanisms responsible for the impact of metastatic tumor growth on the mineral content of the skeleton are complex and involve the stimulation of osteoclasts and osteoblasts by tumor cells expressing factors. The resulting imbalance between resorption and production of bone matrix subsequently leads to osteoclastic, osteoblastic, or mixed metastatic disease (2).

In osteolytic lesions, bone destruction is primarily mediated by osteoclasts and, in later stages, ischemia can play a role due to the compression of the vasculature (15). Parathyroid hormone-related peptide (PTHrP) induces osteoblasts to produce a receptor activator of nuclear factor kB ligand, which stimulates osteoclast maturation, and thereby plays a critical role in the development of osteolytic lesions. Increased osteoclast activity leads to bone resorption that exceeds the reparative ability of osteoblasts (16). It releases factors from the bone matrix that stimulate PTHrP, thereby creating a vicious cycle. In osteoblastic lesions, osteoblast generation is influenced by transforming growth factor, bone morphogenetic proteins (BMP), and endothelin-1 (17). Tumor-derived growth factors stimulate primarily osteoblasts rather than osteoclasts, resulting in deposition of excess abnormal bone. PTHrP can be cleaved by prostate-specific antigen (PSA), resulting in an osteoblastic reaction and decreased bone reabsorption. Furthermore, osteoblast differentiation is influenced by core binding factor alpha, also known as Runx-2 (14). Osteoblast activity may also increase as a reparative process in successfully treated bone metastases, which can be visible on molecular imaging as the so-called “flare phenomenon” and can cause lesions to become denser on radiographs or CT scans (18).

After the tumor cells have left the primary tumor and are in circulation, the bone tumor microenvironment needs to provide a fertile ground (the soil), for the survival and growth of metastatic cancer cells (the seed) (19). Vascular adhesion and extravasation need to occur, and the tumor cells have to remain at the metastatic site. Subsequently, chemo-attractive and adhesion molecules play an important role in the retention of the tumor cells in the bone marrow vasculature. In turn, tumor cells use equivalent molecules, such as chemokines, integrins, osteopontin, bone sialoprotein and type I collagen for organ colonization (20). The microenvironment supports cancer cell survival and growth by producing promoting factors that may contribute to bone metastases development. Subsequently, epithelial-mesenchymal transition occurs, which enables epithelial cells to migrate to a new environment. While this occurs mainly during embryogenesis, in cancer cells this process denotes the invasive phenotype (21).

Sex-associated differences exist in bone metastasis formation from breast-, lung- and prostate cancer. In breast cancer, estrogen influences the bone microenvironment by creating and conditioning a favorable niche for colonization of breast cancer cells. Patients with estrogen receptor α positive (ER+) tumors have bone metastases three times more often than do patients with ER- tumors (22). In lung cancer, it is reported that females more often have bone metastases due to a more favorable bone microenvironment for metastasis formation. In prostate cancer patients, a decrease in the androgen-to-estrogen balance results in bone metastasis formation, with a potentially important role for ERβ that may be similar to that in breast cancer. Androgens as well as estrogens have an influence on osteoblast proliferation and on bone resorbing osteoclasts. In both males and females, estrogens have a dominant effect on bone maintenance and can directly inhibit osteoclasts. Furthermore, androgens directly contribute to male periosteal bone expansion, mineralization, and trabecular bone maintenance (23).

The time from primary diagnosis to the development of bone metastasis can range from months to decades. This implies that tumor cells can lay dormant for significant periods of time after they leave the primary site. It has been shown that the bone is an important reservoir for dormant tumor cells. The best-illustrated cases for clinical dormancy are in breast cancer, where ER+ patients show late recurrences, sometimes decades after removal of the primary tumor. Latent bone metastasis formation likely depends on estrogen regulation, and it is significantly higher in ER+ cases (24).

Bone metastases have unique disease-specific characteristics, such as longevity, fracture healing rates, local and systemic disease progression, and sensitivity to adjuvant treatments. Bone metastases from lung cancer and renal cancer can also show acral distribution (25). Patients with bone metastases of lung cancer historically showed a median survival of approximately 6 months (14). Treatment options for patients with identifiable mutations include immunotherapy and epidermal growth factor receptor tyrosine kinase inhibitors, with evidently improved survival benefit (26). Bone metastases of lung cancer are, in general, sensitive to radiation therapy (27).

The median survival of breast cancer patients with bone-only metastasis is 6 months (28). The medical treatment of breast cancer depends on the hormone receptor and HER-2/neu status and is different for premenopausal and postmenopausal women (25). Furthermore, pain reduction can be achieved, and skeletal-related events and the development of new skeletal lesions can be prevented by the use of bisphosphonates or denosumab, due to their ability to limit bone resorption. Bone metastases of breast cancer are in general radiosensitive, resulting in a lower proportion of surgical treatments (29).
Men with prostate cancer, a good performance status, and bone-only disease have a median duration of disease control after androgen blockade of 4 years and a median survival of 53 months (14). Bone metastases of prostate cancer have a predilection for the axial skeleton, resulting in an increased risk for spinal cord compression (25). However, due to the osteoblastic nature of the metastases, skeletal-related events are relatively uncommon. Also, bone metastases of prostate cancer tend to be radiosensitive, which allows a higher proportion of nonsurgical treatment. In case of a pathologic fracture, healing rates are higher than for most other metastatic carcinomas (29). Treatment with Radium-223, a calcium-mimetic and alphasaturating agent that selectively binds to areas of increased bone turnover, results in significantly prolonged OS in patients who had castration-resistant prostate cancer and bone metastases (30).

**LESSONS LEARNED FROM EXPERIMENTAL IMAGING**

Quantitative imaging of bone metastases beyond morphology has been studied in preclinical studies on the functional and molecular level using MRI and PET. In these studies, quantitative biomarkers in skeletal lesions were assessed and validated with the underlying histology. Thereby, DCE-MRI parameters in bone metastatic lesions from breast cancer associated with blood volume and vessel permeability were correlated with vessel maturity, while the apparent diffusion coefficient (ADC) from DWI was associated with tumor cellularity as assessed by cell nuclei staining (31). Treatment monitoring in an animal model of osteolytic breast cancer could be performed reliably using DCE-MRI and 18F-FDG PET, while therapy response could be detected through functional and metabolic techniques earlier than through morphological imaging (32, 33). Integration of parameters from DCE-MRI and 18F-FDG PET by machine learning algorithms enabled the detection of early pathologic processes in the bone marrow preceding morphologic changes in bone structure (34). Thus, parameters from functional and metabolic MR and PET imaging are powerful tools to quantify pathophysiologic processes during colonization of bone marrow and to determine response to treatment of skeletal metastasis.

On the molecular level, PET is the method of choice to determine molecular structures expressed in bone metastases, such as integrins αVβ3/5 or the chemokine receptor CXCR4 (35, 36). Although a major limitation of MRI is the lack of sensitivity when compared to PET, a strategy of signal amplification using a pair of enzymes and an appropriate reducing substrate was presented recently to non-invasively assess epidermal growth factor receptor (EGFR) expression in MRI (37). Besides MRI and PET, other imaging modalities may also be used to determine molecular information in bone metastases, such as ultrasound with its high spatial resolution and unique contrast characteristics of gas-filled microbubbles for enabling the assessment of intra-vascular targets such as vascular endothelial growth factor receptor-2 (VEGFR-2) expressed in bone metastases (38). Thus, molecular imaging strategies for molecular characterization of skeletal lesions have been developed for PET but also for MRI and ultrasound, which are suitable for clinical translation in the near future.

**MAGNETIC RESONANCE IMAGING (MRI)**

**From Axial Spine-MRI to Whole Body-MRI With Diffusion-Weighted Imaging**

Since the early 1990s, bone marrow MRI has been developed to overcome the limitations of bone scintigraphy and CT for the assessment of bone metastatic disease, showing an unparalleled sensitivity to the replacement of the bone marrow by neoplastic cells (39, 40).

Axial skeleton MRI (AS-MRI) examinations was first developed as a tool used for the detection of bone marrow replacement by neoplastic foci and their quantification (40, 41). Coverage of the “axial skeleton”, i.e. the whole spine, bony pelvis and proximal femurs, already probes more than 80% of the red marrow containing areas where metastatic disease is observed, and has limited risk to miss isolated peripheral metastatic disease (39, 42).

Whole body MRI (WB-MRI) was later developed for a global assessment of skeletal metastases and for a one-step “all-organ” approach of metastatic disease. The morphologic T1, fat saturated T2/STIR sequences were first used, and were later complemented with functional DWI sequences (42). The “fluid sensitive-fat saturated” T2-like sequences are now preferably acquired using the Dixon method, that not only provides fat-saturated T2 or STIR equivalent “water only” images, but also “fat only” images providing T1-like information and highly sensitive detection of focal lesions on a background of fatty marrow, questioning the residual need for T1 images (43). This T2 Dixon approach can now be extended to whole body examinations: using T2 Dixon sequences as an alternative to the addition of T1 and STIR drastically decreases the acquisition times of anatomical WB-MRI studies (44). Additionally, the Dixon technique offers the possibility to calculate the marrow fat fraction (FF) and generate fat fraction maps. This quantitative approach is gaining interest along with ADC measurements as a biomarker for response evaluation. Indeed, the fat proportion is expected to increase in focal and diffuse marrow infiltration in response to treatment (45).

**Principles, Advantages and Weaknesses**

Classic morphologic MRI sequences detect metastases based on the decrease in normal marrow components, mainly fat cell, and on their replacement by neoplastic cells which may present different biochemical composition properties and variable influence on the adjacent bone structure (46).

DWI sequences detect metastatic foci based on the alteration of the movements of water molecules through tissues. In the bone marrow, early infiltration by neoplastic cells is responsible for a decrease in the free movements of water and ADC (47). DWI sequences provide a functional dimension to MRI examinations, as diffusion parameters mainly probe membrane
integrity, cell viability and tissue density, and allow a quantitative approach of these parameters. It also largely contributes to the detection and response evaluation in extraskeletal organs involved by the metastatic disease (11, 48, 49).

The detection of neoplastic tissue using MRI does not rely on activation of osteoblasts/clasts and subsequent sclerosis/lysis developed on bone trabeculae, which causes delay in the diagnosis of bone infiltration by radiographs, CT and bone scintigraphy. Unlike PET, MRI does not rely on the avidity of the tumoral tissue for a given radioactive tracer, which largely varies according the primary cancer and also according to the disease stage in the same cancer (50). This provides a “universal” dimension to MRI for the detection and follow-up of metastatic disease.

A major strength of MRI is the detailed morphologic analysis of bones, which allows distinction of benign versus malignant fractures, assessment of extraosseous spread and (sometimes preclinical) impingement on neurologic structures, and monitoring of these complications after initiation of targeted or systemic treatment (51).

As main weaknesses, some benign bone lesions may mimic neoplastic foci and should be identified based on the correlation of DWI and morphologic sequences and on ADC measurements (52, 53). In late stages of the disease, treated lesions and scar tissue within the bone marrow may complicate the detection and size measurements of active metastases, especially on morphologic sequences. DWI sequences and ADC maps then become cardinal for response assessment (54–56).

Another potential limitation of MRI is a benign increase in marrow cellularity of the red bone marrow during the treatment, in response to various factors among which are marrow stimulating drugs, potentially resulting in a diffuse “pseudoprogression” (57). This can be prevented by avoiding the use of MRI during and shortly after the use of these drugs.

Measurement of Response

Bone marrow MRI is currently used daily in clinical practice and clinical trials to assess the response to treatment of bone only and bone predominant metastatic disease, using several approaches with different complexity (18, 58). Recommendations for a homogenization of MRI image acquisitions and generalizable response criteria have been developed (55). The harmonization of quantitative DWI acquisitions and ADC calculations has been addressed by the United Kingdom Quantitative WB-DWI Technical Workgroup (59).

Size and Number

Metastatic disease to the bone marrow may present as a focal or a diffuse pattern. Evolution from a normal appearing marrow to a focal or diffuse pattern, increase in number and size of focal lesions will indicate disease progression (60). A decrease in focal lesion number and size, return from diffuse or focal patterns of marrow infiltration to a normal marrow appearance will indicate response (Figures 1, 2).

RECIST-like criteria can be transposed to bone marrow metastases. Simple size measurements of bone metastases on morphologic sequences in (a limited sample of) bone metastases allows objective assessment of response, especially in early disease. This approach can be used on morphologic sequences and on high b value DWI sequences. In prostate cancer, this approach more than doubles the proportion of patients with measurable metastatic disease, previously limited to those patients with quantifiable abdominal lymph nodes (41).

Non-Quantitative Features

Additional “qualitative” signs may be used for response assessment on MR images. The progressive appearance of a “fatty halo” of high signal on T1-weighted images at the periphery of regressing focal lesions indicates responsive disease (60). Conversely, the disappearance of a peripheral “cellular” of high signal intensity on T2-weighted images, representing active or aggressive disease, also represents an early sign of response, whereas its re-appearance suggests disease relapse. The appearance of malignant vertebral compression fractures, and appearance/progression of extraosseous/epidural spread unambiguously indicate progressive disease (60).

Quantitative Functional and Multiparametric Approaches

The quantitative approach can be directed either to individual lesions or to the whole-skeleton using ADC measurements and mapping derived from DWI sequences and fat fraction (FF) measurements derived from Dixon acquisitions. This approach becomes cardinal in advanced metastatic disease where previously treated lesions and scar tissue complicate the size measurements of active lesions on morphologic sequences.

Response to treatment is associated with an early increase in ADC values within individual lesions (61). At a later stage, responsive bone metastases present a decrease in ADC values together with a decreased signal on high b-value images due to recolonization by normal bone marrow. A sharper decrease in signal intensity and ADCs is related to the sclerotic transformation of treated lesions, which is also observed on anatomic sequences. A total diffusion volume can be derived from WB DWI sequences for a global quantification of the metastatic burden and its follow-up under treatment (62, 63). The FF presents an early increase in focal and diffuse metastatic infiltration in response to treatment (45).

Multiparametric MRI by definition combines anatomical and at least two functional sequences. The multiparametric WB-MRI approach used for the quantitative evaluation of bone lesions combines anatomical T1 and STIR sequences (potentially replaced by single T2 Dixon acquisitions), FF measurements, and functional DWI sequences along with ADC maps.

The METastasis Reporting and Data System for prostate cancer (MET-RADS-P) guidelines were designed in prostate cancer, in an international initiative to standardize WB-MRI protocols and most importantly to provide multiparametric response evaluation criteria for bone, node, and visceral lesions (55). These criteria combine quantitative approaches of ADC and FF within bone marrow metastases, RECIST-like size criteria transposed to bone lesions, and RECIST criteria for node and visceral lesions follow-up. They allow categorization of the disease response or progression on a 5-point Likert scale. The method also offers the possibility to record the heterogeneity of response within metastases and
categorizes the response as “discordant” if some bone lesions or soft-tissue are progressing, while others are stable or are responding, and vice-versa. The reproducibility of the technique as well as its use by readers with various experience have been validated (64). The same criteria may be transposed for WB-MRI studies performed for lesion follow-up and response assessment in bone-only or bone-predominant metastatic disease from other primary cancers.

**Target Cancers**

The objective parameters extracted from AS-MRI and WB-MRI/DWI are increasingly used to assess response of bone metastases to treatment in a large number of primary cancers.

In prostate cancer, AS-MRI and later WB-MRI were introduced after demonstration of their superiority to bone scintigraphy for detection of bone metastases and for a one step staging of bone and lymph node involvement (40, 65, 66). The current roles of WB-MRI to assess metastatic disease have been recently illustrated and compared to other techniques (44). PSMA-PET/CT is most likely the current most sensitive technique for the detection of low volume metastatic disease and for therapeutic decision (curative versus systemic treatment) in newly diagnosed prostate cancer and at the biochemical recurrence stage. WB-MRI is an optimal non-irradiating alternative for polymetastatic disease detection and follow-up.
under systemic treatment (Figure 2). WB-MRI might become the first choice in advanced disease, castration-resistant prostate cancer (CRPC), as PSMA-PET/CT might be confounded by androgen blockade (AB) treatments which induce short term upregulation of PSMA expression and long term downregulation of this expression, limiting the possibility of following metastatic prostate cancer lesions at this stage (67, 68).

In breast cancer, AS-MRI and WB-MRI were also introduced to overcome the limitations of bone scintigraphy (BS) and CT for the detection of bone metastases and evaluation of their response to treatment (Figure 1A) (54, 69, 70). WB-MRI progressively becomes a key imaging modality for the evaluation of response in bone only/predominant metastatic breast cancer for the follow-up of treatment response (71). In patients with advanced breast cancer treated with systemic treatment of metastatic disease and followed-up with WB-MRI in addition to other imaging modalities (CT, BS, TAP-CT or PET/CT), WB-MRI discloses progressive disease earlier than the reference examination and provides decisive information for changes in treatment in more than 50% of patients (72–74). Of note, WB-MRI shows a frequent discrepancy between response as assessed locally within the primary cancer and within metastases, and disease progression is identified earlier in distant disease compared to local disease assessment (75).

There is a consistently increasing number of indications of WB-MRI for bone and visceral metastases detection in various primary cancers, sometimes relying on the design of disease- or patient-tailored MRI studies (coverage of lung, liver, and brain, with specific sequences according to primary cancer). WB-MRI can for example be proposed in this indication in lung, thyroid, kidney and colorectal cancers, in melanoma, myxoid liposarcoma, Ewing sarcoma or osteosarcoma. The detection of bone metastases using the same technique substantiates its use for the subsequent evaluation of the response of bone lesions to treatment (76).

**POSITRON EMISSION TOMOGRAPHY (PET)**

**Quantitative Assessment of Bone Metastases on PET**

Traditionally, PET is used for staging of many cancer types because of its high sensitivity for visual detection of metastatic disease, typically using 18F-FDG as radiotracer. In 2009, novel qualitative and quantitative approaches to metabolic tumor response assessment, solely applicable for 18F-FDG PET, were proposed (77). The purpose was to overcome the limitations of morphologic imaging alone-based criteria (e.g. RECIST, RECIST1.1) and to capitalize the benefit of using newer cancer therapies. The framework for PET Response Criteria in Solid Tumors (PERCIST), version 1.0, was meant to serve as an example for use in clinical trials and in structured quantitative clinical reporting (77).
In current practice, however, the quantitative nature of PET is often unexploited. Especially in the case of bone metastases that are deemed non-measurable by RECIST 1.1, quantification of radiotracer uptake might prove crucial for assessing bone disease through changes in the viability or molecular processes of tumor cells instead of lesion morphology. A further advantage is that quantitative PET assessment can be performed on a per-lesion basis, as well as on a whole-body level.

Parameters that can be extracted from routinely acquired static whole-body PET images have been validated for many tracers in different cancer types (78–82). In general, these parameters can be divided into those based on (83): i) tracer uptake intensity (e.g. standardized uptake values, SUVs), ii) metabolically active tumor volumes (MATV), and iii) a combination of both, representing the total tracer uptake in a tumor. Typical SUV metrics are the mean uptake (SUV\text{mean}), the maximum uptake (highest voxel value; SUV\text{max}), or the peak uptake (highest average value of a 1cm³ sphere; SUV\text{peak}) within an identified lesion. Depending on specific radiotracer kinetics, uptake may need to be normalized to background activity in e.g. liver or blood (81). Metrics combining lesion volume and tracer uptake, such as total lesion glycolysis (TLG) for ¹⁸F-FDG, seem especially promising for objective longitudinal assessment of bone metastases load, as they provide information on the total amount of viable tumor tissue within a bone lesion both on an individual lesion and patient-basis (84, 85).

**Target Cancers**

**Prostate Cancer**

In metastatic prostate cancer, osteoblastic or mixed bone lesions with minor soft tissue component are frequently observed, challenging accurate RECIST1.1-based follow-up for these patients. With the recent introduction of several PET-tracers targeting the PSMA (Figure 3), detection of prostate cancer lesions has significantly improved (86, 87). In 2018, guidelines for standardized interpretation of PSMA PET images (PROMISE) were proposed (88). Quantitative parameters for evaluation of treatment response using PSMA PET/CT, besides well-known maximum standardized uptake values (SUV\text{max}), have been proposed including PSMA tumor volume (PSMA-TV) and total lesion PSMA expression (TL-PSMA) (85). Initial studies evaluating metrics such as PSMA-TV and TL-PSMA for metabolic response assessment have shown promising results, some of these through a ‘PSMA-modified’ RECIST or PERCIST classification system. Importantly, several studies reported an association of these PSMA PET parameters with overall survival (OS) during treatment with radioligand therapy (RLT) with ¹⁷⁷Lu-PSMA (89–91). A recent systematic review summarized the available evidence for using quantitative PSMA parameters versus serum PSA in assessing response for castration-resistant prostate cancer (92).

In parallel to ER-targeted PET imaging in breast cancer with 6α-¹⁸F-fluoro-17β-estradiol ([¹⁸F]FES), androgen receptor (AR)-targeted PET imaging in prostate cancer is possible using ¹⁸F-fluorodihydrotestosterone (¹⁸F-FDHT; Figure 3), which binds the intracellular AR in prostate cancer cells (93). This enables quantitative assessment of AR-expression in bone metastases, both for response monitoring and prognostic purposes (80, 93, 94). ¹⁸F-FDHT cannot be used during treatment with drugs that directly block the AR (95, 96). For PSMA-ligands and ¹⁸F-FDHT, technical validation studies assessing tracer pharmacokinetics and repeatability have been evaluated.
performed, enabling their clinical use in (quantitative) response assessment (80, 81, 94, 97, 98).

The PET response assessment approach for bone metastases in prostate cancer using PSMA PET may be extended to other targeted PET tracers, such as 18F-NaF and 18F-FDHT in prostate cancer, 18F-FES in breast cancer and 18F-FDG and 68Ga-fibroblast activation protein inhibitors (68Ga-FAPI) in a multitude of cancer types (94, 99–102).

**Lung Cancer**

The skeleton is the most common site of distant metastasis in lung cancer. Approximately 30% to 40% of the patients with advanced cancer will develop bone metastases, which represent 10% of disease recurrence even in early stage operable lung cancer (15, 103, 104). 18F-FDG PET/CT plays a key role in the diagnostic work-up of lung cancer, being fundamental especially at diagnosis and during staging/restaging (105). Consequently, all clinical guidelines support the use of the modality for the assessment of advanced disease (106–110), given the high diagnostic accuracy in depicting distant metastases for which 18F-FDG PET/CT results superior to other conventional imaging (111–115).

Recent meta-analysis data comparing [18F]FDG PET/CT with WB-MRI show similar performances for staging NSCLC, i.e. area under the curve (AUC) 0.95 for PET versus 0.93 for MRI (116). The performance was also similar in case of SCLC patients (117). When considering only bone metastases, dedicated meta-analyses in lung cancer have proven PET/CT is superior to other modalities, with a pooled sensitivity for [18F]FDG PET/CT, MRI and bone scintigraphy (BS) of 92%, 77% and 86%, respectively, associated to a pooled specificity of 98%, 92% and 88%, respectively (118). Depending on cancer type, there is also an associated impact in patient management that ranges from 12%–40% of the cases (105, 111, 115, 118).

**Breast Cancer**

The use of 18F-FDG PET/CT in breast cancer faces more conflicting indications based on major clinical guidelines (111, 119, 120). While staging in advanced or suspicious metastatic breast cancer is widely supported, initial preoperative staging is regarded of limited value. Still, the results of a recent meta-analysis in 4276 patients prove that the use of 18F-FDG PET for initial evaluation of breast cancer leads to a change in staging and management in 25% and 18% of patients, respectively (121). With younger age, clinical stage III to IV and histologic grade II to III were significantly associated with a greater proportion of changes. These results are most likely attributable to the superior diagnostic accuracy of 18F-FDG PET/CT compared with other modalities (122, 123). In particular, the pooled sensitivity and specificity of whole-body 18F-FDG PET and PET/CT are reported to be 99% and 95%, respectively, compared to 57% and 88% for conventional imaging studies (8, 124).

Approximately 70%–80% of breast cancers express hormone receptors (HR), i.e. ERα and/or progesterone receptors (PR) (125). Thanks to the use of [18F]FES PET, breast cancer metastases can be characterized non-invasively also for ER status reaching a pooled sensitivity and specificity of 78% and 98%, respectively (126, 127). The information obtained by [18F]FES PET can be used also to predict the response to hormonal therapy in patients with locally advanced or metastatic breast cancer. For this purpose, SUV cut-off values can be applied, for example 1.5 and 2.0, demonstrating pooled sensitivities and specificities for response prediction of 63.9% vs. 66.7%, and 28.6% vs. 62.1%, respectively (127). In newly diagnosed ER-positive breast cancer, moreover, [18F]FES PET shows a sensitivity of 90.8% versus 82.8% for 18F-FDG PET/CT, thus potentially leading to a change in patient management in 26.3% of the cases (128).

Besides overexpression of hormone receptors, a proportion of breast cancer tumors is known to show expression of human epidermal growth factor receptors 2 (HER2) (129). In recent years, whole body HER2-targeted PET imaging has proven to be a valuable tool, both for the identification of patients suitable for anti-HER2 therapy and monitoring therapeutic efficacy (130–135). HER2 can be targeted by several inhibitors that directly block the receptors on HER-expressing tumor cells or interfere with their signaling pathways (135). HER2-targeted PET imaging with 64Cu- or 89Zr-labeled antibodies is effective but typically requires late time points acquisitions due to the antibody and radio-isotope properties (132, 133). 68Ga-labeled antibody molecules targeting HER2 allow for routine same-day PET imaging, thereby improving the clinical utility of HER2-targeted imaging, and have yielded promising initial results (130, 131, 136). More clinical data on the use of HER2-targeted molecular imaging in breast cancer patients is required before future clinical use.

**Challenges and Opportunities in PET**

Absolute measurements of tumor lesion PET metrics are inherently dependent on the method used for tumor delineation (137). Several segmentation methods have been proposed, most semi-automatic and relatively easy to apply, requiring a good repeatability and reproducibility basis in order to detect small changes during response monitoring (138, 139). Software packages are often vendor-supplied and differences between several methods have been well evaluated (139–141).

Evaluating longitudinal changes in tracer uptake on PET typically requires patients to be scanned on preferably the same PET/CT system using the same image reconstruction protocol (142–144). Still, in PET the technical uncertainties can be easily mitigated by harmonization of PET/CT system performances between and within clinical centers. The latter is achieved by the EARL accreditation program showing that harmonization is feasible and is a prerequisite for a high reproducibility of quantitative reads (145, 146).

Besides technical challenges, biological aspects need to be considered when using PET for measuring bone lesions and response to treatment in a clinical setting. The optimal timing of disease assessment will depend on the specific treatment type a patient is receiving, such as radiotherapy, RLT, chemotherapy, or other targeted drugs. For example, systemic cytotoxic or antihormonal treatments may elicit so called ‘flare’ phenomena, potentially precluding the use of PET early during treatment follow-
up (147–150). This can be avoided by adhering to clinical guidelines and not performing PET too soon after treatment initiation.

Recent and ongoing technical advances have given rise to several new opportunities in PET imaging. PET initially was a stand-alone modality, but has moved on to become a hybrid imaging modality (with CT and MRI). Even more recently, the novel ‘total body’ PET systems have become available (151, 152). These total body (or ‘long axial field of view’) PET systems can be used to perform PET imaging in a single field-of-view instead of multiple bed positions, with typical FOV from skull apex to mid-thighs (151–153). Not only does this severely shorten the required acquisition time (a large benefit for patients with often painful bone metastases), but this is also accompanied by a large increase in system sensitivity which is expected to improve lesion detection rates (153). Moreover, the total body PET might enable quantitative parameters incorporating radiotracer dynamics, such as whole body Patlak (154), to be extracted and parametric images to be generated.

Advances in computer science have made the routine use of artificial intelligence (AI) in medical imaging analysis possible (155). A common application of AI in PET lies in the analysis and modeling of radiomics features. Radiomics pertain to large volumes of data on tumor shape, size, metabolism and texture that can be extracted from PET-positive lesions, providing an image-based tumor phenotype (155–157). The Imaging Biomarker Standardization Initiative has harmonized performance of radiomics software packages to allow for its robust and reproducible use (157). Recently, consensus recommendations for considerations on the use of radiomics (both PET, CT, and MRI) in clinical trials have been proposed (158). Deep learning techniques, which do not require extraction of predefined features seem particularly promising for segmentation purposes of PET-avid bone metastases (159, 160). For PSMA PET, a deep learning algorithm for automated analysis of PET images (‘aPROMISE’) has been developed (161).

HYBRID IMAGING (PET/MRI)

The unique potential of hybrid imaging, as reviewed by Schmidkonz and colleagues, lies in the assessment of complementary parameters on the morphologic, functional, metabolic and molecular levels of bone metastases from different modalities in a single examination (162). When combining PET with CT in a PET/CT study, the CT component enables assessment of bone morphology and osseous destruction, while MRI in a PET/MRI hybrid study will offer superior soft tissue contrast. Due to the (still) novelty and increased cost and allocation of PET-positive findings were found to be superior to PET/CT (163). Samarín and colleagues reported similar results from a comparison of 18F-FDG PET/CT with 18F-FDG PET/MRI in 24 patients with bone metastases from different primary tumors (164). The overall detection rate was not significantly different between PET/CT and PET/MRI, but the latter provided higher reader confidence and improved conspicuity as compared with PET/CT (164).

In a prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI and CT, PET/MRI was significantly better than CT for the detection of bone metastases in patients with newly diagnosed breast cancer (165). Also, in a particular series of 109 breast cancer patients, PET/MR demonstrated an improved sensitivity over 18F-FDG PET/CT alone, where the sensitivity of PET/MR and PET/CT were 96% and 85%, respectively (166). In men with biochemical recurrence of prostate cancer following curative therapy, 68Ga-PSMA-11 PET/MRI demonstrated a high detection rate especially for recurrent disease with low PSA values, but included all sites of local or distant recurrence including lymph nodes and bone (167). In 26 patients with prostate cancer, 68Ga-PSMA-11 PET/MRI and PET/CT performed equally regarding the PET component for detection of bone metastases, while two PET-positive skeletal metastases could be confirmed on contrast MRI, but not on CT (168).

An interesting approach for patients with both osteolytic and osteoblastic metastases from breast or prostate cancer was proposed by Sonni and colleagues (169). Combining 18F-FDG and Na18F in PET/MRI was superior for the detection of skeletal metastases as compared to whole-body bone scintigraphy (169). This approach includes in an innovative manner both a radiotracer (Na18F) for the assessment of primarily osteoblastic activity in osteoblastic lesions, and another tracer (18F-FDG) for assessing increased glucose metabolism in the soft tissue component of predominantly osteolytic metastases. Based on the data and results referenced above, PET/MRI appears rather superior to PET/CT for the detection of metastatic bone lesions, but it lacks the morphologic information of bone and osteoblastic bone formation derived from the CT component, which might be mitigated some through innovative approaches as reported by Sonni and co-workers.

BEYOND RECIST AND PERCIST

In 2009, the PET Response Criteria in Solid Tumors (PERCIST) were introduced for 18F-FDG PET (77). Later on, along with the detailed describing of the 18F-FDG PET requirements to allow quantitative expression of the changes in PET measurements and assessment of overall treatment response, a Simplified Guide to PERCIST 1.0 was published (170). The PERCIST criteria enable avid bone target lesions to be selected based on their metabolic activity, and response to be measured objectively based on the changes in metabolic activity even in the absence of an evident anatomic change. PERCIST, however, only considers the change in uptake of a single target lesion when assessing response, which is the lesion with the highest SUV_LINEAR value normalized for lean body mass (SUL_LINEAR). New lesions, in the bone or elsewhere, result in progressive disease by definition. The target lesion may or may not...
be within the bone, but all bone lesions have to be considered in the selection of target lesion. Of note, there is no impact of changes in volume of lesions, only the uptake concentration is considered. Compared to RECIST, PERCIST represents a major step forward for bone assessment as it considers bone lesions equally to any other lesions anywhere else in the body.

The PERCIST approach focuses on the remaining hottest lesion and has similarities with the therapy response criteria for lymphoma, where the most active remaining lesions play a dominant role (171). This “hottest lesion” centric approach is well tailored to therapies with curative intent, but it might miss a beneficial effect in non-curative therapies, where tumor control and tumor bulk reduction are clinically relevant achievements. A recent approach in image analysis is about abandoning the selection of target lesions, as determined on baseline or post-therapy scans, and aiming to take the entire tumor bulk in consideration. The high contrast of modern oncological PET tracers [e.g., 18F-FDG, somatostatin receptor (SSTR) and PSMA ligands, 18F-DOPA, 18F-MFBG (172)] permits straightforward three-dimensional segmentation of lesions; by segmenting all lesions, the total tumor burden can then be obtained. This type of analysis does not distinguish between bone and non-bone lesions and thus puts bone metastases on par with other metastases.

There is evidence that the baseline metabolic tumor volume (MTV) is an important prognostic factor, e.g. in NHL, NSCLC and multiple myeloma, as well as in prostate cancer patients treated with the bone-seeking agent radium-223 (173–176). Furthermore, MTV can be combined with metrics of tumor distance within a patient to not only represent volume, but also dissemination for better reflecting prognosis, as shown in NHL (175). Evaluation of the changes in MTV and/or TLG have been shown to outperform PERCIST-based approaches in tumors with frequent bone lesions, such as Ewing sarcoma and osteosarcoma (177–180). Volumetric determination on PET is not hampered by bone/soft tissue interfaces, taking the total tumor burden into account in combination with the metabolic activity. Total tumor burden analyses can be combined with specific organ segmentation either based on PET or CT, e.g. for spleen (for lymphoma) and bone, to generate organ-specific tumor burden (181, 182). Furthermore, the segmentation leading to total tumor burden or organ-specific tumor burden can also be used as a mask to determine specific radiomic features, which can provide even more information for response evaluation (180).

Although promising, some challenges remain to the application of tumoral volumes for routine therapy response monitoring: (i) lack of standardization of uptake thresholds for PET-positive tumor delineation; (ii) still too time consuming for clinical routine; (iii) no prospectively defined response criteria. Especially regarding i and ii, it is expected that advances in tumor segmentation, e.g. with further automatization of the segmentation process and contributions from deep learning-based AI algorithms, will increase the robustness, accuracy and feasibility of total tumor segmentation to routine clinical practice levels (141, 183). Based on results from current and ongoing studies, automated tumor segmentation should actually be one of the key expected improvements from AI applications to PET (and other) imaging (160).

At any rate, similar analyses can be developed for non-FDG tracers, e.g. with SSTR ligands in neuroendocrine tumors and PSMA ligands in prostate cancer, Na18F in breast and prostate cancer patients (184–187). For evaluation of response on PSMA PET, consensus criteria have recently been proposed with specific cut-off values for both uptake and volume (188).

A specific case of total tumor burden imaging that is worthy to mention is the use of the bone scan index (BSI), which is a metric based on 2D planar bone scintigraphy that reflects the fraction of bone showing increased turnover due to metastatic invasion (189). It has been proposed two decades ago as a metric for tumor burden and response assessment in metastatic prostate cancer (189). Changes in BSI under treatment have been shown to correlate with OS in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with a range of therapies (190). This has been corroborated in multicenter trials in mCRPC patients treated with abiraterone acetate and with radium-223 dichloride (191, 192). Although promising, it is expected that the shift from 2D to 3D imaging and the increasing use of novel PET tracers that can pick up lesions outside of the bone as well as bone lesions (e.g. PSMA ligands) will eventually displace the currently widespread adoption of BSI for therapy response. Accordingly, similar but PET-based metrics from PSMA and/or Na18F PET will likely outperform and replace BSI.

CONCLUSION

Modern imaging with PET and MRI allows bone metastases to be detected and assessed both before and after therapy, without the drawbacks of X-ray based imaging techniques (e.g. radiographs, CT). These techniques assess bone metastases within the same framework, as metastases in other organs. They further allow total tumor burden to be assessed within a single imaging session, and also the development of response criteria that include the bone, thus filling a critical gap in the RECIST1.1 framework. The EORTC, PERCIST and recent PSMA PET criteria are examples of criteria that take bone metastases in consideration, on-par with extra-osseous lesions. PET and/or MRI can detect and characterize bone metastases of various types (e.g. lytic, sclerotic, radio-occult or mixed) independently from the bone density changes. In contrast with CT, they are not affected by changes in bone mineralization induced by the tumor(s), and are not dependent on soft-tissue components (as required by RECIST 1.1). Whole body MRI including modern techniques such as DWI, DCE-MRI and mpMRI can provide both detailed information on anatomical structures as well as functional information on individual lesions and whole body tumor burden. Modern PET imaging is performed on hybrid cameras, with CT (from PET/CT) allowing assessment of the bone mineral content (including fractures), while MRI (from PET/MRI) can more often clarify a correlate for the lesions observed on PET. Total tumor burden, incorporating bone metastases on par with other metastases, is an attractive approach to be applied in most PET tracers. While advances in algorithms and deep-learning contributions are expected to permit the determination of total tumor burden
metrics in actual clinical routine before and after therapy, response criteria through total tumor burden assessment are currently developed, taking into consideration the tracer, therapy and underlying cancer type.

REFERENCES

1. Moreira CA, Dempster DW, Baron R. Anatomy and Ultrastructure of Bone - Histogenesis, Growth and Remodeling. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al, editors. Endotext. South Dartmouth (MA): MDText.com, Inc. (2000).

2. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases. Clin Cancer Res (2006) 12(20 Pt 2):6213s-6s. doi: 10.1158/1078-0432.\textit{CLINICAL}2006-06-1007

3. Clezardin P. Pathophysiology of Bone Metastases From Solid Malignancies. Joint Bone Spine (2017) 84(6):677–84. doi: 10.1016/j.jbspin.2017.05.006

4. Messiou C, Cook G, Reih AH, Attard G, Dearnaley D, de Bono JS, et al. The CT Flare Response of Metastatic Bone Disease in Prostate Cancer. Acta Radiol (2011) 52(5):537–61. doi: 10.1258/ar.2011.100342

5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 92(3):205–16. doi: 10.1093/jnci/92.3.205

6. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New Response Evaluation Criteria in Solid Tumors: Revised RECIST Guideline (Version 1.1). Eur J Cancer (2009) 45(2):228–47. doi: 10.1016/j.ejca.2008.10.026

7. Spiro SG, Buscombe J, Cook G, Eisen T, Gleeson F, O’Brien M, et al. Ensuring the Right PET Scan for the Right Patient. Lung Cancer (2008) 59(1):48–56. doi: 10.1016/j.lungcan.2007.07.026

8. Paydary K, Seraj SM, Zadeh MZ, Emamzadehfard S, Shamchi SP, Gholami S, et al. The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. Mol Imaging Biol (2019) 21(1):1–10. doi: 10.1007/s11307-018-01183-1

9. Stecco A, Trisoglio A, Soligo E, Berardo S, Sukhovei L, Carriero A. Whole-Body MRI With Diffusion-Weighted Imaging in Bone Metastases: A Narrative Review. Diagnostics (Basel) (2018) 8(3):45. doi: 10.3390/diagnostics8030045

10. Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, et al. Whole-Body Diffusion-Weighted MR Imaging for Assessment of Treatment Response in Myeloma. Radiology (2014) 271(3):785–94. doi: 10.1148/radiol.13131529

11. Lecouvet FE, Van Nieuwenhove S, Jamar F, Lhommel R, Guermazi A, Chrousos G, de Herder WW, Dhatariya K, et al, editors. Molecular Imaging of Bone Metastases and Their Response to Therapy. J Nucl Med (2020) 61(6):799–806. doi: 10.2967/jnumed.119.234260

12. Hillengass J, Ritsch J, Merz M, Stadler M, Merz M, Seyler L, Bretsch M, Semmler W, et al. Drug-Induced Vessel Remodeling in Bone Metastases As Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A Longitudinal In Vivo Study. Clin Cancer Res (2010) 16(12):3215–25. doi: 10.1158/1078-0432.CCR-09-2932

13. Merz M, Komljencovic D, Zwick S, Semmler W, Bauerle T. Safety of Denosumab Versus Bisphosphonates in Breast Cancer and Bone Metastases: A Retrospective Case-Control Study. Bone. Cancer Metastasis Rev (2001) 20(3-4):333–49. doi: 10.1023/A:1015599813232

14. Cook GJR, Goh V. Molecular Imaging of Bone Metastases and Their Response to Therapy. J Nucl Med (2020) 61(6):799–806. doi: 10.2967/jnumed.119.234260

15. Coleman RE. Metastatic Bone Disease: Clinical Features, Pathophysiology and Treatment Strategies. Cancer Treat Rev (2001) 27(3):165–76. doi: 10.1053/ctrv.2000.0210

16. Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, et al. Immunohistochemical Localization of Parathyroid Hormone-Related Protein in Human Breast Cancer. Cancer Res (1990) 50(23):7710–6.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.
Ligand PET/CT in Patients With Castration-Sensitive Prostate Cancer. *Eur J Nucl Med Mol Imaging* (2018) 45(12):2045–54. doi: 10.1007/s00259-018-4027-0.

68. Liu T, Wu LY, Fulton MD, Johnson JM, Berkman CE. Prolonged Androgen Deprivation Leads to Downregulation of Androgen Receptor and Prostate-Specific Membrane Antigen in Prostate Cancer Cells. *Int J Oncol* (2012) 41(6):2087–92. doi: 10.3892/ijo.2012.1649.

69. Schmidt GP, Baur-Melnich A, Haug A, Heinemann V, Bauerfeind I, Reiser MF, et al. Comprehensive Imaging of Tumor Recurrence in Breast Cancer Patients Using Whole-Body MRI at 1.5 and 3 T Compared to FDG-PET-CT. *Eur J Radiol* (2008) 65(1):47–58. doi: 10.1016/j.ejrad.2007.10.021.

70. Nakaniishi K, Kobayashi K, Nakagaki K, Kyakuno M, Hashimoto N, Onishi H, et al. Whole-Body MRI for Detecting Metastatic Bone Tumor: Diagnostic Value of Diffusion-Weighted Images. *Magn Reson Med Sci* (2007) 6(3):147–55. doi: 10.2463/mrms.6.147.

71. A zadG K, Taylor BP, Green A, Sandri I, Swampilla A, Harris M, et al. Patterns of Disease Progression in Patients With Local and Metastatic Breast Cancer as Evaluated by Whole-Body Magnetic Resonance Imaging. *Breast* (2018) 40:82–4. doi: 10.1016/j.breast.2018.04.019.

72. Kosmin M, Makris A, Joshi PV, Ah-See ML, Woolf D, Padhani AR. The Addition of Whole-Body Magnetic Resonance Imaging to Body Computerised Tomography Alters Treatment Decisions in Patients With Metastatic Breast Cancer. *Eur J Cancer* (2017) 77:109–16. doi: 10.1016/j.ejca.2017.03.001.

73. Zugni F, Ruju F, Piccolo P, Alessi S, Iorfida M, Colleoni MA, et al. The Added Value of Whole-Body Magnetic Resonance Imaging in the Management of Patients With Advanced Breast Cancer. *PloS One* (2018) 13(10):e0205251. doi: 10.1371/journal.pone.0205251.

74. Kosmin M, Padhani AR, Gogbashian A, Woolf D, Ah-See ML, Oxtler P, et al. Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. *Radiology* (2020) 297(3):622–9. doi: 10.1148/radiol.2020192683.

75. Kosmin M, Padhani AR, Sokhi H, Thijssen T, Makris A. Patterns of Disease Progression in Patients With Local and Metastatic Breast Cancer as Evaluated by Whole-Body Magnetic Resonance Imaging. *Breast* (2018) 40:82–4. doi: 10.1016/j.breast.2018.04.019.

76. Jacobs MA, Macura KJ, Zaheer A, Antonarakis ES, Stearns V, Wolff AC, et al. *Management of Patients With Advanced Prostate Cancer: Comparison of [(18)F] Fluorodeoxyglucose and [(18)F]-Fluoride PET/CT With Whole-Body MRI With Diffusion-Weighted Imaging.* *Eur J Nucl Med Mol Imaging* (2019) 46(4):821–30. doi: 10.1007/s00259-018-4223-9.

77. Zaidi H, Karakatsanis N, Towards Enhanced PET Quantification in Clinical Oncology. *Br J Radiol* (2018) 91(1081):20170508. doi: 10.1259/bjr.20170508.

78. Schwartz J, Grkovski M, Rimner A, Schoder H, Zanzonico PB, Carlin SD, et al. Pharmacokinetic Analysis of Dynamic (18)F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer. *J Nucl Med* (2017) 58(6):911–9. doi: 10.2967/jnumed.116.180422.

79. Rosar F, Hau F, Bartholoma M, Maus S, Stemler T, Linxweiler J, et al. Molecular Imaging and Biochemical Response Assessment After a Single Cycle of [(225)Ac]Ac-PSMA-617/[(177)Lu]Lu-PSMA-617 Tandem Therapy in Mrcp Patients Who Have Progressed on [(177)Lu]-PSMA-617 Monotherapy. *Theranostics* (2021) 11(9):4050–60. doi: 10.7150/thno.36211.

80. Scher HI, Beer TM, Higano CS, Andreeva A, Tannir NM, Cheng L, et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. *Acad Radiol* (2018) 25(11):1405–14. doi: 10.1016/j.acra.2018.02.010.

81. Wadhil R, Jaco H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. *J Nucl Med* (2009) 50 Suppl 1:1225–50S. doi: 10.2967/jnumed.108.057307.

82. Frings V, Yaqub M, Hoeyng LL, Golla SS, Windhorst AD, Schuit RC, et al. Assessment of Simplified Methods to Measure 18F-FLT Uptake Changes in Patients With Castration-Resistant Prostate Cancer. *Eur J Nucl Med Mol Imaging* (2014) 41(11):11–20. doi: 10.1007/s00259-013-2525-5.

83. Zaidi H, Karakatsanis N. Towards Enhanced PET Quantification in Clinical Oncology. *Br J Radiol* (2018) 91(1081):20170508. doi: 10.1259/bjr.20170508.

84. Zaidi H, Karakatsanis N. Towards Enhanced PET Quantification in Clinical Oncology. *Br J Radiol* (2018) 91(1081):20170508. doi: 10.1259/bjr.20170508.

85. Vargas HA, Schuit RC, Windhorst AD, et al. Initial Experience With Volumetric (68)Ga-PSMA I&T Molecular Imaging and Biochemical Response Assessment After Prostatectomy: A Prospective, Single-Centre, Single-Arm, Comparative Imaging Trial. *Lancet Oncol* (2019) 20(9):1286–94. doi: 10.1016/S1470-4247(19)30415-2.

86. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET Imaging With A (68)Ga-Labelled PSMA Ligand and (18)F-Choline-Based PET/CT for the Diagnosis of Recurrent Prostate Cancer. *Eur J Nucl Med Mol Imaging* (2014) 41(11):11–20. doi: 10.1007/s00259-013-2525-5.

87. Vargas HA, Schuit RC, Windhorst AD, et al. Initial Experience With Volumetric (68)Ga-PSMA I&T Molecular Imaging and Biochemical Response Assessment After Prostatectomy: A Prospective, Single-Centre, Single-Arm, Comparative Imaging Trial. *Lancet Oncol* (2019) 20(9):1286–94. doi: 10.1016/S1470-4247(19)30415-2.

88. Vargas HA, Schuit RC, Windhorst AD, et al. Initial Experience With Volumetric (68)Ga-PSMA I&T Molecular Imaging and Biochemical Response Assessment After Prostatectomy: A Prospective, Single-Centre, Single-Arm, Comparative Imaging Trial. *Lancet Oncol* (2019) 20(9):1286–94. doi: 10.1016/S1470-4247(19)30415-2.
Oprea-Lager et al. Bone Metastases Are Measurable

Using [68Ga]Ab-P-025 Ablifody Pet/Theranostics (2016) 6(2):262–71. doi: 10.7150/thno.13502

13. Vandermeulen L, Luidd P, Wiimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular Imaging as a Tool to Investigate Heterogeneity of Advanced HER2-Positive Breast Cancer and to Predict Patient Outcome Under Trastuzumab Emtansine (T-DM1): The ZEPHIR Trial. Ann Oncol (2016) 27(4):619–24. doi: 10.1093/annonc/mdv577

133. Mortimer JE, Badjing JR, Park JM, Frankel PH, Carroll MI, Tran TT, et al. Tumor Uptake of (64)Cu-DOTA-TRastuzumab in Patients With Metastatic Breast Cancer. J Nucl Med (2018) 59(1):38–43. doi: 10.2967/jnm.njnm.17.193888

134. Kramer-Marck G, Bernardo M, Kiesewetter DO, Bagi U, Kuban M, Aras O, et al. PET of HER2-Positive Pulmonary Metastases With 18F-2HER2:342 Ablifody in a Murine Model of Breast Cancer: Comparison With 18F-FDG. J Nucl Med (2012) 53(6):939–46. doi: 10.2967/jnm.njnm.11.100354

135. Kramer-Marck G, Oyen WJ. Targeting the Human Epidermal Growth Factor Receptors With Immuno-PET: Imaging Biomarkers From Bench to Bedside. J Nucl Med (2016) 57(7):996–1001. doi: 10.2967/jnm.njnm.115.169540

136. Sandstrom M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D, et al. Biodistribution and Radiation Dosimetry of the Anti-HER2 Ablifody Molecule 68Ga-ABY-025 in Breast Cancer Patients. J Nucl Med (2016) 57(6):867–71. doi: 10.2967/jnm.njnm.115.169342

137. Boelhaar R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of Noise, Image Resolution, and ROI Definition on the Accuracy of Standard Uptake Values: A Simulation Study. J Nucl Med (2004) 45(9):1519–27.

138. Kolinger GD, Vallez Garcia D, Kramer GM, Frings V, Smit EF, de Langen AJ, et al. Repeatability of [(18)F]FDG PET/CT Total Metabolic Active Tumor Volume and Total Tumor Burden in NSCLC Patients. EJNMRI Res (2019) 9(1):14. doi: 10.1186/s13550-019-0481-1

139. Frings V, van Velden FH, Velasquez LM, Hayes W, van den Ven PM, Hoekstra OS, et al. Repeatability of Metabolically Active Tumor Volume Measurements With FDG PET/CT in Advanced Gastrointestinal Malignancies: A Multicenter Study. Radiology (2014) 273(2):539–48. doi: 10.1148/radiol.14132807

140. Hartrampf PE, Heinrich M, Seitz AK, Brumberg J, Sokolakis I, Kalogirou C, et al. Molecular Imaging of Prostate Cancer Patients During Chemotherapy-Do Different Software Solutions Deliver Comparable Results? J Clin Med (2020) 9(5):1390. doi: 10.3390/jcm9051390

141. Gafita A, Bieth M, Kronke M, Tetteh G, Navarro F, Wang H, et al. Qpsma: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using (68)Ga-PSMA11 PET/CT. EJNMRI Phys (2019) 33(5):1277–84. doi: 10.1186/s40658-019-0257-8

142. Kaalep A, Burggraaf CN, Piepenbosch S, Verwer EE, Sera T, Zijlstra J, et al. Quantitative Implications of the Updated EARL 2019 PET-CT Performance Standards. EJNMRI Phys (2019) 6(1):28. doi: 10.1186/s40658-019-0257-8

143. Deviere J, Beels L, Maes A, Van de Wiele C, Pottel H. Impact of PET Reconstruction Protocols on Quantification of Lesions That Fulfil the PERCIST Lesion Inclusion Criteria. EJNMRI Phys (2018) 8(1):35. doi: 10.1186/s40658-018-0235-6

144. Quak E, Le Roux PY, Hofman MS, Robin P, Bourhis D, Callahan J, et al. Harmonizing FDG PET Quantification While Maintaining Optimal Lesion Detection: Prospective Multicentre Validation in 517 Oncology Patients. Eur J Nucl Med Mol Imaging (2015) 42(13):2072–82. doi: 10.1007/s00259-015-3128-0

145. Kaalep A, Sera T, Rijnsdorp S, Yaqub M, Talsma A, Lodge MA, et al. Performance of Whole-Body Integrated 18F-FDG PET/MR Increases Diagnostic Confidence in Detection of Bone Metastases Compared With 18F-FDG-PET/CT. Eur J Nucl Med Commun (2021) 48(2):285–94. doi: 10.1007/s00259-020-07598-8

146. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, et al. Ablifody: A Novel Automated-PROMISE Platform to Standardize Image Resolution, and ROI De-...
Oprea-Lager et al. Bone Metastases Are Measurable

[Page 17]

Conflict of Interest: KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ARX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymbas, all outside the submitted work. CD reports consultancy for Sirtex, Terumo and PSI CRO, speaker fees from Terumo and Advanced Accelerator Applications and is a member of advisory board for Terumo and Ipsen. EL reports grants from Fondazione AIRC and Italian Ministry of Health, royalties from Springer, lecturer fees from Mi&T congressi and ESMIT. LF reports speaker fees from SanoFil, Novartis, Janssens, and General Electric, congress sponsorship from Guerbet, industrial grant on radiomics from Invensys and Novartis, and co-investigator in grant with Philips, Ariana Pharma, Evolucare.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in

[Remaining text is not provided due to the nature of the provided snippet.]

Frontiers in Oncology | www.frontiersin.org 17 November 2021 | Volume 11 | Article 772530

[Page 18]
